Bizarre Patents
A coffin, for allowing inclination for display of a deceased person in a natural position.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8440446 | Bacteriophage strains for the treatment of bacterial infections, especially drug resistant strains of the genus Novel bacteriophage strains are disclosed and their use in the production of preparations for use in the treatment of bacterial infections, particularly with drug resistant strains of bacteria of the genus Enterococcus, particularly those belonging to the spe... | 05/14/2013 |
| 8377477 | Method for production of bioresorbable microparticles, microparticles thus obtained and use thereof The present invention relates to a method for preparing nonlamellar bioresorbable microparticles to which protein substances are bonded, characterized in that it comprises the steps of: (i) preparing said microparticles from at least one bioresorbable p... | 02/19/2013 |
| 8372955 | Purified antibody to the extracellular domain of NKp44L The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infec... | 02/12/2013 |
| 8372407 | Chimeric HIV fusion proteins as vaccines A method for inducing HIV antigen-specific immune responses is disclosed. The method comprises administering to a subject in need thereof a therapeutically effective amount of a chimeric fusion protein comprising: (a) a first polypeptidyl region comprising a Pseu... | 02/12/2013 |
| 8361473 | Antibodies and their uses for diagnosis and treatment of cytomegalovirus infection and associated diseases Anti CMV antibodies are provided. Thus an antibody of the present invention comprises an antigen recognition domain capable of binding an MHC molecule being complexed with a cytomegalovirus (CMV) pp65 or pp64 peptide, wherein the antibody does not bind said MHC mole... | 01/29/2013 |
| 8338180 | Methods for treating lentivirus infections The present invention provides methods of identifying an agent that inhibits an activity of a lentiviral Vif protein. The present invention provides methods of identifying an agent that increases the level of active APOBEC3G in a cell. The present invention provides... | 12/25/2012 |
| 8338582 | Anti-HIV immunogens and methods for inducing an immune response The present invention refers to new epitopes recognized by CD4+ T-lymphocytes. In addition, the present invention refers to the uses of such epitopes and their combinations, particularly in the treatment or prevention of disorders caused by the HIV-1 virus. T... | 12/25/2012 |
| 8333971 | Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments The present invention concerns methods and compositions for treatment of HIV infection in a subject. The compositions may comprise a targeting molecule against an HIV antigen, such as an anti-HIV antibody or antibody fragment. The anti-HIV antibody or fragment may b... | 12/18/2012 |
| 8329393 | Method for detecting and removing endotoxin The present invention relates to bacteriophage tail proteins and the derivatives and fragments thereof that are capable of binding endotoxins in the absence of bivalent positive ions, especially Ca2+ or Mg2+. Further, the present invention rela... | 12/11/2012 |
| 8329442 | bacteriophage and antibacterial composition comprising the same Disclosed herein are is a novel bacteriophage which has specific bactericidal activity against one or more Salmonella bacteria selected from the group consisting of Salmonella Enteritidis, Salmonella Typhimurium, Salmonella Gallinarum, and Salmonell... | 12/11/2012 |
| 8323961 | HIV vaccines based on adenoviral vectors encoding Env from multiple clades of HIV The invention provides a composition comprising four adenoviral vectors, each comprising a nucleic acid sequence encoding a clade A HIV Env protein, a clade B HIV Env protein, a clade C HIV Env protein, and a clade B HIV Gag-Pol fusion protein, respectively. The inv... | 12/04/2012 |
| 8293515 | bacteriophage and antibacterial composition comprising the same Disclosed herein is a novel bacteriophage which has specific bactericidal activity against one or more Salmonella bacteria selected from the group consisting of Salmonella Enteritidis, Salmonella Typhimurium, Salmonella Gallinarum, and Salmonella Pu... | 10/23/2012 |
| 8293280 | Method for treatment of HIV infection A method for treatment of HIV infection includes administering at least one anti-HIV drug, such as a reverse transcriptase inhibitor, to a patient in need of such treatment and administering an extract from inflammatory tissue inoculated with vaccinia virus to the p... | 10/23/2012 |
| 8288146 | bacteriophage and antibacterial composition comprising the same The present invention relates to a novel bacteriophage, more particularly, a bacteriophage that has a specific bactericidal activity against Salmonella typhimurium, Salmonella gallinarum, or Salmonella pullorum, a composition for the prevention or trea... | 10/16/2012 |
| 8278432 | HBV drug resistance methods New polymorphisms in the nucleic acid sequences of the DNA polymerase/reverse transcriptase open reading frame and viral surface antigen open reading frame of the hepatitis B virus are reported. In particular, the present invention relates to the mutation YMDD→YSD... | 10/02/2012 |
| 8273564 | Disinfectant composition comprising phage of The present invention provides a disinfectant composition including a phage of Acinetobacter baumannii and a carrier. The present invention also provides a method for disinfecting a medical institute or a medical research institute, including the steps of app... | 09/25/2012 |
| 8268974 | Process to produce fibrillar proteins A method for changing a globular protein structure into a fibrillar protein structure. The method comprising the steps of providing a globular protein, forming a solution containing the globular protein, adding a detergent to the solution containing the globular pro... | 09/18/2012 |
| 8247613 | Methods and compositions for the synergistic activation of latent HIV The present invention provides methods and compositions useful for the elimination of latent HIV reservoirs that persist despite HAART. The methods and compositions overcome this latent barrier by inducing the replication of HIV in latently infected T cells while pr... | 08/21/2012 |
| 8216780 | Method for enhanced sensitivity in bacteriophage-based diagnostic assays A method of determining the presence or absence of a target microorganism in a sample to be tested, the method comprising: (a) combining with the sample an amount of bacteriophage capable of attaching to the target microorganism to create a bacteriophage-exposed sam... | 07/10/2012 |
| 8216595 | Powerful vaccine composition comprising lipopeptide and poly I:C as an adjuvant The present invention relates to an adjuvant comprising a lipopeptide and poly I:C. When the adjuvant of the present invention is used, the level of antigen specific antibody induction is synergistically increased and Th1 type immune response is also induced. Theref... | 07/10/2012 |
| 8211879 | Cationic steroid antimicrobial compositions and methods of use The invention provides methods for decreasing or inhibiting herpesviridae (HV) infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with a herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo, or an... | 07/03/2012 |
| 8187872 | Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein Lentiviral vector particles comprising a Sindbis virus E2 glycoprotein variant and a lentiviral vector genome comprising a sequence of interest are provided. A lentiviral vector particle comprising: (a) an envelope comprising a Sindbis virus E2 glycoprotein variant;... | 05/29/2012 |
| 8178657 | Polypeptide sequence involved in the modulation of the immunosuppressive effect of viral proteins The present invention relates to a polypeptide having a sequence of 7 to 20 amino acid residues, which is capable of modulating the immunosuppressive properties of a viral protein or a fragment thereof, against the host in which it is expressed (immunosuppression-mo... | 05/15/2012 |
| 8168769 | HPV vaccines and methods for using the same Improved anti-HIV immunogens and nucleic acid molecules that encode them are disclosed, Immunogens disclosed include those having consensus sequences for HIV Subtype A Envelope protein, those having consensus sequences for HIV Subtype B Envelope protein, those havin... | 05/01/2012 |
| 8148131 | Bacteriophage and antibacterial composition comprising the same The present invention relates to a novel bacteriophage, more particularly, a bacteriophage that has a specific bactericidal activity against Fowl Typhoid causing Salmonella Gallinarum (SG) and Pullorum disease-causing Salmonella Pullorum (SP). Further,... | 04/03/2012 |
| 8148129 | Generation of potent dominant negative transcriptional inhibitors The present invention provides methods and compositions for regulating gene expression using transcription factors linked to proteins that localize to the transcriptional machinery. ... | 04/03/2012 |
| 8110204 | Method of treating human-immunodeficiency virus (HIV) disease infection Human Immunodeficiency virus causes depletion of CD4 cells. The depletion of CD4 cells results in decrease in immunity of an infected individual. Due to decrease immunity various opportunistic infections occur. These infections are cause for mo... | 02/07/2012 |
| 8105578 | Treatment of neoplasms with viruses The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are us... | 01/31/2012 |
| 8076085 | Methods and means relating to hepatitis B infection The present inventors have discovered that the presence of antibodies reactive with residues 94-117 of the PreS1 component of the hepatitis B surface antigen (HBsAg) in an individual with HBV infection correlates closely with the effectiveness of interferon (IFN) in... | 12/13/2011 |
| 8071352 | Bacteriophage having killing activity specific to The present invention relates to a novel bacteriophage, more precisely a novel bacteriophage having killing activity specific to Staphylococcus aureus which is the causing agent of infectious diseases in human and animals, a pharmaceutical composition for the... | 12/06/2011 |
| 8043611 | Regulated nucleic acid expression system The present invention provides nucleic acid constructs, expression systems, and methods relating to the regulation of gene expression. The invention may be applied to regulate the expression of any coding sequence of interest, including those coding for viral compon... | 10/25/2011 |
| 8043612 | Infection and treatment of neoplasms with vesicular stomatitis virus The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are us... | 10/25/2011 |
| 8034899 | HIV fusion inhibitor peptides with improved biological properties Provided is an HIV fusion inhibitor peptide having an amino acid sequence of any one of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO:15; and provided is a pharmaceutical composition comprising a HIV fusion inhibitor... | 10/11/2011 |
| 8003313 | Method for detecting and removing endotoxin The present invention relates to bacteriophage tail proteins and the derivatives and fragments thereof that are capable of binding endotoxins in the absence of bivalent positive ions, especially Ca2+ or Mg2+. Further, the present invention rela... | 08/23/2011 |
| 7985573 | Targeted drug-carrying bacteriophages The present invention relates to the field of drug delivery. More specifically, the invention relates to the preparation and use of a bacteriophage conjugated through a labile/non labile linker or directly to at least 1,000 therapeutic drug molecules such that the d... | 07/26/2011 |
| 7972773 | Method for detecting concentrations of a target bacterium that uses phages to infect target bacterial cells The invention is directed to a method for detecting low concentrations of bacteria in liquid solution that may or may not be complex liquid solutions. In one embodiment, immunomagnetic separation (IMS) is used to separate target bacterium that may be in a liquid mix... | 07/05/2011 |
| 7959928 | VLP-antigen conjugates and their uses as vaccines The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising a virus-like particle (VLP) of an RNA-bacteriophage and at least one antigen, wherein the VLP is recombinantly pro... | 06/14/2011 |
| 7947822 | HIV vaccines based on Env of multiple clades of HIV The invention provides a composition comprising a pharmaceutically acceptable carrier and six plasmids, each of which encodes an HIV Env, Gag, Pol, or Nef protein. The invention also provides a method of inducing an immune response in an animal using the composition... | 05/24/2011 |
| 7943140 | Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of HIV-1 A self-adjuvanting immunogenic composition comprising multiple immunogens, each immunogen comprising a lipopeptide cap, a universal T helper sequence and an immunodominant HIV-1 Tat B cell epitope. The immunogen also comprises one or more linker sequences and/or pol... | 05/17/2011 |
| 7932074 | Multivalent human-bovine rotavirus vaccine The present invention provides vaccine compositions for protection against human rotaviral disease without significant reactogenicity. Human×bovine reassortant rotavirus comprising each of the four clinically most important VP7 serotypes of human rotavirus are comb... | 04/26/2011 |
